Active	Status	Sponsor type	Region	Phase	Filter
8 Active 3 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hardeman, Amelia
Lilly-I3Y-US-I026, NCT04791384: Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer	Recruiting	1/2	44	US	Abemaciclib, Verzenio, Elacestrant	Criterium, Inc.	Breast Cancer	12/24	01/25
OP-1250-003, NCT05508906: Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus	Recruiting	1	155	US, RoW	OP-1250, Ribociclib, KISQALI®, Alpelisib, PIQRAY®, Everolimus	Olema Pharmaceuticals, Inc., Novartis	Metastatic Breast Cancer, Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Breast Cancer	05/26	06/26